Sickle Cell Disease
Anthera gets approval to start phase II IMPACTS trial in patients with sickle cell disease
Published in Health Business Week, February 9th, 2007
The IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) trial is a multicenter phase 2 clinical study aimed at preventing a severe respiratory complication of sickle cell disease, acute chest syndrome. Acute chest syndrome, a form of acute lung injury, is the leading cause of death in sickle cell disease patients. It commonly follows admission to the hospital for other reasons, especially an episode of bone pain (a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2007-02-09)
More Articles from Health Business Week
- Accreditation
Vested Health health plan receives URAC consumer education and support accreditation - Acid Suppression
Study finds first-day acid suppression similar in two top-selling OTC heartburn treatments - Acute Myeloid Leukemia
Xanthus receives orphan drug designation of Xanafide for treating acute myeloid leukemia - Acute Radiation Syndrome
U.S. FDA clears Humanetics' IND filing to commence clinical studies on new radiation countermeasure - Addiction Medicine
Stanford study will test antidepressant patch that may help smokers kick the habit - Addiction Medicine
Study results on memory's link to recovering from addiction published in Harvard newsletter - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
